Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review by Kulier, Regina et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Reproductive Health
Open Access Research
Effectiveness and acceptability of progestogens in combined oral 
contraceptives – a systematic review
Regina Kulier*1, Frans M Helmerhorst2, Nandita Maitra3 and A 
Metin Gülmezoglu4
Address: 1Geneva Foundation for Medical Education and Research, Geneva, Switzerland, 2Leiden University Medical Center, Leiden, Netherlands, 
3Medical College Surat, Baroda, India and 4UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research 
Training in Human Reproduction, WHO Geneva, Switzerland
Email: Regina Kulier* - regina.kulier@gfmer.ch; Frans M Helmerhorst - F.M.Helmerhorst@LUMC.nl; 
Nandita Maitra - nanditamaitra@hotmail.com; A Metin Gülmezoglu - gulmezoglum@who.int
* Corresponding author    
Abstract
Background: The progestogen component of oral contraceptives (OCs) has undergone changes
since it was recognized that their chemical structure can influence the spectrum of minor adverse
and beneficial effects.
Methods:  The objective of this review was to evaluate currently available low-dose OCs
containing ethinylestradiol and different progestogens in terms of contraceptive effectiveness, cycle
control, side effects and continuation rates. The Cochrane Controlled Trials Register, MEDLINE
and EMBASE databases were searched. Randomized trials reporting clinical outcomes were
considered for inclusion and were assessed for methodological quality and validity.
Results:  Twenty–two trials were included in the review. Eighteen were sponsored by
pharmaceutical companies and in only 5 there was an attempt for blinding. Most comparisons
between different interventions included one to three trials, involving usually less than 500 women.
Discontinuation was less with second-generation progestogens compared to first–generation (RR
0.79; 95% CI 0.69–0.91). Cycle control appeared to be better with second-compared to first-
generation progestogens for both, mono-and triphasic preparations (RR 0.69; 95% CI 0.52–0.91)
and (RR 0.61; 95% CI 0.43–0.85), respectively. Intermenstrual bleeding was less with third-
compared to second-generation pills (RR 0.71; 95% CI 0.55–0.91).
Contraceptive effectiveness of gestodene (GSD) was comparable to that of levonorgestrel (LNG),
and had similar pattern of spotting, breakthrough bleeding and absence of withdrawal bleeding).
Drospirenone (DRSP) was similar compared to desogestrel (DSG) regarding contraceptive
effectiveness, cycle control and side effects.
Conclusion: The third- and second-generation progestogens are preferred over first generation
in all indices of acceptability. Current evidence suggests that GSD is comparable to LNG in terms
of contraceptive effectiveness and for most cycle control indices. GSD is also comparable to DSG.
DRSP is comparable to DSG. Future research should focus on independently conducted well
designed randomized trials comparing particularly the third- with second-generation progestogens.
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Background
Combined oral contraceptives (OCs) were first intro-
duced for clinical use in the 1960's. Ethinylestradiol (EE)
has been the most commonly used estrogen component.
In order to reduce the side effects and increase the accept-
ability, the EE dose was gradually reduced to 30 micro-
grams (mcg) or less and the biochemical structure of the
progestogens was changed. The progestogen dose,
though, cannot be reduced nowadays since further reduc-
tion may not prevent the LH-surge and thus allow ovula-
tion. The different progestogens can be classified
according to their steroid structure and to their timing of
market introduction. All contraceptive progestogens have
a similar steroid skeleton with 4 rings and can be catego-
rized into three tetracyclic structures: the pregnanes
(derived from the progesterone molecule), the estranes
(derivatives of testosterone) and the gonanes [1] (table 1).
Estranes correspond to first generation progestogens, such
as norethisterone (NE), norethindrone (NE), ethynodiol
diacetate, lynestrenol (LYN) and norethynodrel as well as
dienogest. Dienogest is derived from NE and is claimed to
have no androgenic activity and lesser effect on glucocor-
ticoids than mifepristone [1]. Gonane progestogens are
divided into two classes: the second-generation pro-
gestogens levonorgestrel (LNG) and norgestrel (NG) and
third-generation progestogens desogestrel (DSG),
gestodene (GSD) and norgestimate (NGM). Examples of
pregnanes in OCs are cyproterone acetate (CPA), chlo-
rmadinone acetate and nomegestrol.
Although norethynodrel was the progestogen component
in the very first OC, norethisterone (as known in Europe)
or norethindrone (NE) can be considered as the most
important substances in the early period of oral contra-
ception. The first-generation progestogens norethynodrel,
norethisterone acetate, and lynestrenol are all metabo-
lized to NE and were nearly always combined with 50 µg
of EE or more. The synthesis of norgestrel (NG) in 1963
by Smith [2] was followed by the isolation of the biologi-
cally active component, levonorgestrel (LNG) [3]. These
second-generation progestogens entered the market in the
1970s. Currently, LNG is probably the most widely used
progestogen and predominantly combined with 30 µg EE.
During the 1980s, three new progestogens forming the
third-generation progestogens, desogestrel (DSG),
gestodene (GSD) and norgestimate (NGM) were devel-
oped by three different pharmaceutical companies. DSG
and NGM are both pro-drugs. DSG is activated in the
body by conversion into 3-keto-DSG, whereas NGM is
converted by biotransformation into several metabolites,
one of which is LNG. Unclassified in generations are such
progestogens as CPA (listed in the pregnane classification,
not introduced into the US market) and drospirenone
(DRSP), a recently introduced progestogen derived from
17-α-spironolactone that might possess antimineralcorti-
coid and mild antiandrogenic activity.
Methods
Outcomes
The objective of the review was to compare the various
currently available low dose OCs containing different pro-
gestogens and assess their acceptability according to the
following indicators:
1. Effectiveness (pregnancy rates)
2. Discontinuation rates
3. Reasons for discontinuation
4. Cycle control
5. Side-effects
Trials had to report clinical outcomes to be eligible for
inclusion. Trials focusing on biochemical changes only
were not eligible for the review. The primary outcome of
interest in this review is acceptability.
Contraceptive effectiveness
For contraceptive effectiveness (incidence of pregnancy)
we used the authors' definition and did not differentiate
between method and user failure. The failure rate of
Table 1: Progestogens [1]
Pregnanes Estranes Gonanes
2nd generation 3rd generation
Chlormadinone acetate Norethindrone acetate dl-Norgestrel Desogestrel
Cyproterone acetate Ethynodiol diacetate Levonorgestrel Gestodene
Nomegestrol, Nestorone Lynestrenol Norgestimate
NorethynodrelReproductive Health 2004, 1 http://www.reproductive-health-journal.com/content/1/1/1
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combined oral contraceptives varies with age, race and
marital status in typical users of OCs. The lowest expected
failure rate is thought to be around 0.1% with perfect use
(theoretical efficacy) and the higher failure rates observed
in typical users (effectiveness) are largely attributed to
problems with compliance [4].
Discontinuation
Data on discontinuation rate and the reasons for discon-
tinuation are important measures of acceptability.
Cycle control
Women's acceptance of a hormonal contraceptive
method depends largely on the degree of cycle control and
side effects [5]. In fact, a diminishing compliance due to
poor cycle control will also affect the effectiveness of the
method. Lack of standardization in the reporting and
analysis of intermenstrual bleeding patterns prevents
meaningful comparisons of the new formulations from
one study to another [6]. The changes in cycle patterns
were analysed separately from side-effects, according to
the type of change, if possible (e.g. breakthrough bleed-
ing, intermenstrual bleeding, spotting, absence of with-
drawal bleeding).
Common side-effects
The common side-effects associated with OC use are
reported as breast tenderness, headache, migraine, nau-
sea, nervousness, vomiting, dizziness, weight gain, tired-
ness, decline of libido and increase in blood pressure. The
side-effects can be due to estrogen, progestogen or andro-
gen effects and can decrease after a few months of use [7].
It is not always possible to attribute a side-effect to the
estrogen or to the progestogen component.
Rare adverse events
Both estrogen and progestogen component of combined
OCs are believed to be responsible for cardiovascular
events associated with OC use. Venous events have often
been associated with the estrogen component. Associa-
tion of acute myocardial infarction, stroke and venous
thromboembolism with OC use has been studied exten-
sively generating considerable controversy. These rare
long term adverse events are not amenable to study
through randomized controlled trials, hence, these events
are not the focus of this review.
Types of interventions
1. Any monophasic low-dose estrogen (<50 mcg) com-
bined OC containing a third-generation progestogen ver-
sus any monophasic low-dose estrogen combined OC
containing a second-generation progestogen (same for
multiphasic preparations)
2. Any monophasic low-dose estrogen combined OC con-
taining a third generation progestogen versus any
monophasic low-dose estrogen combined OC containing
a first-generation progestogen (same for multiphasic
preparations)
3. Any monophasic low-dose estrogen combined OC con-
taining a second-generation progestogen versus any
monophasic low-dose estrogen combined OC containing
a first-generation progestogen (same for multiphasic
preparations)
4. Comparisons between low-dose estrogen OCs contain-
ing a certain type of progestogen.
Search strategy
1. We searched the Cochrane Controlled Trials Register,
MEDLINE and EMBASE with the following search
strategy:
CONTRACEPTIVES-ORAL*:ME
LEVONORGESTREL
NORETHISTERONE
norethyndrone
NORETHINDRONE
NORGESTIMATE
DESOGESTREL
GESTODENE
(((((((#1 or #2) or #3) or #4) or #5) or #6) or #7) or #8)
MENOPAUS*
NORPLANT
REPLACEMENT
ANIMAL
INJECT*
CANCER
IUD
INTRAUTERINE
PROSTAT*Reproductive Health 2004, 1 http://www.reproductive-health-journal.com/content/1/1/1
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((((((((#10 or #11) or #12) or #13) or #14) or #15) or
#16) or #17) or #18)
(#9 not #19)
2. Letters requesting information from pharmaceutical
companies who have combined low-dose estrogen OCs
containing different progestogens were sent.
3. Informal contacts with researchers in the field were
made to identify any trials.
The reports identified with the electronic search were
checked initially for two characteristics:
1. Random allocation to comparison groups
2. Clinical outcomes reported
If these characteristics were not clear from the title or the
abstract the full report was retrieved. Reports that have
met above criteria were assessed for other inclusion crite-
ria, methodological quality and validity of the data. Both
application of inclusion criteria and the data extraction
were made by the reviewers independently and differ-
ences were resolved by discussion.
Types of studies
Randomized controlled trials comparing low-dose estro-
gen (<50 mcg) combined oral contraceptive (OC) formu-
lations were eligible. Cross-over studies were not
considered. Trials had to include women of reproductive
age, using OCs for contraception, irrespective of the dura-
tion of past OC use, or being new starters or switchers. Tri-
als enrolling volunteers for biochemical change
assessments or women receiving OCs for non-contracep-
tive purposes (such as acne vulgaris) were not eligible.
Comparisons between same phasic dosages were eligible.
A trial comparing a monophasic OC with a multiphasic
OC was not eligible even if the progestogens were within
the scope of the review.
Interventions had to be applied for a minimum of six
months for a trial to be considered for inclusion.
In addition to the clinical outcomes, systematic data
extraction was carried out for each trial for the following
variables:
Methodology
Random allocation techniques, blinding, post-randomi-
zation exclusions and loss to follow-up (intention-to-
treat). Trials were given a quality score for the conceal-
ment of allocation as described in: Mulrow CD, Oxman
AD (eds). Cochrane Collaboration Handbook [updated 1
March 1997]. In: The Cochrane Library [database on disk
and CD ROM]. The Cochrane Collaboration. Oxford:
Update Software; 1996-. Updated quarterly.
Demographic characteristics
Type of health care setting, city, country, total number of
women included, and inclusion and exclusion criteria.
Information on funding for the study and potential con-
flicts of interest were extracted if reported.
We used relative risk (RR) to report measures of effect and
the random effects model.
Trials were excluded if there were unexplained imbalances
of loss to follow-up in numbers between the comparison
groups.
Trials were searched for, regardless of their language.
When there was more than one time period reported for
an outcome (e.g. pregnancy after six months, one year)
the longest follow-up data were extracted. The rest of the
data are discussed in the text if warranted.
For cycle related side effects, stratification according to the
dose of estrogen used was performed when possible.
Definitions
Low-dose OC refers to the EE content of <50 mcg.
Regarding cycle disturbances: definitions are used as they
were made by the individual authors of the trials.
Results
Twenty-two trials were included in the review.
Description of studies
The trials were conducted in many diverse settings and
some were multicenter trials including centers from sev-
eral countries (table 2). The participants were usually
described as women seeking contraception excluding
those with medical conditions not suitable for OC use.
Some trials reported selected outcomes such as cycle con-
trol but not other components of acceptability [8,9]. Thir-
teen studies clearly stated the inclusion and exclusion
criteria. Both starters and switchers were included. Only
one study [10] mentions a washout period of one cycle
amongst the switchers prior to starting the study medica-
tion. In the study by Rossmanith [8], 40% of the switchers
received the same OC before as after the randomization.
The Zichella [11] trial recruited only starters, defined as
women who had not used hormonal contraception for
three months prior to study. Eleven trials were conducted
in Europe, six in the United States and Canada, two inReproductive Health 2004, 1 http://www.reproductive-health-journal.com/content/1/1/1
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Latin America and two in South East Asia. The study by
Dunson [12] was set across all major continents.
Pill composition and regimen
Eighteen trials used OCs distributed as 28-day cycles with
21 active pills and 7 days of no tablet taking. One trial
[13] distributed one OC as a 24-day formulation with all
active pills compared to a 21-day cycle. Another trial used
28-day packages for both groups, with 21 active hormone
tablets and 7 iron tablets for one group and 7 inactive tab-
lets for the other group [12]. We were unable to find infor-
mation on the duration of OC dosing used for two trials
[9,14].
The day of pill start varied within and between studies to
either a first-day start, first-Sunday start or fifth-day start.
Thirteen trials had no information on the day of pill start.
Shoupe used first-Sunday start for both OCs [15]. Day-1
start for both pill types was used in six trials [13,16-20].
First Sunday and day 1 start for the two OC formulations
was used in one trial [21]. Fifth day start for both OC types
was advocated in the study by Ramos [22].
Sponsorship
Eighteen out of 22 trials were supported by pharmaceuti-
cal companies, one trial was jointly supported by a phar-
maceutical company and an international organization
(UNFPA) [22], whereas 2 studies were supported or con-
ducted by international organizations, NGOs or univer-
sity departments [12,21]. There is no information on
funding for 2 trials [8,17].
Comparisons
Twenty-two trials were included in the review. The order
in which the comparisons are arranged is based on the
type of formulation (monophasic or triphasic) and type
of progestogen (newer progestogens versus older pro-
gestogens) following the criteria given by Henzl [1]. Trials
were only included if the difference of the total ethi-
nylestradiol content did not exceed 105 mcg. Sixteen trials
compared monophasic OCs and 6 compared triphasic
OCs [8,15,21,23-25]. Except for two trials using dros-
pirenone [10,26] all other trials included progestogens
categorised as first-, second- or third-generation. No trials
included other progestogens such as ethynodiol diacetate,
Table 2: Included studies and quality assessment
Study Sponsorship Intervention Methods
Randomization Allocation 
concealment
Blinding Intention to 
treat analysis
Affinito [18] Pharmaceutical company GSD vs NGM unclear unclear not unclear
Droegemüller [8] No information LNG vs NE unclear unclear not yes
Dunson [12] Family Health 
International
NG vs NE unclear adequate not not
Endrikat [19] Pharmaceutical company GSD vs DSG unclear unclear not yes
Endrikat [20] Pharmaceutical company LNG vs NE unclear unclear not yes
Foidart [26] Pharmaceutical company DSG vs DRSP unclear unclear not unclear
GSD group [13] Pharmaceutical company GSD vs DSG unclear unclear not yes
Halbe [29] Pharmaceutical company GSD vs DSG unclear unclear not yes
Huber [10] Pharmaceutical company DSG vs DRSP unclear unclear not yes
Koetsawang [28] Pharmaceutical company GSD vs DSG unclear unclear not unclear
L. America [27] Pharmaceutical company GSD vs DSG block randomisation unclear not yes
Loudon [17] No information GSD vs LNG unclear unclear double blind unclear
Percival [23] Pharmaceutical company NG vs NE random list unclear investigator blind unclear
Rabe [14] Pharmaceutical company GSD vs LNG unclear unclear not yes
Ramos [22] Pharmaceutical company 
and UNFPA
LNG vs NE unclear unclear double blind yes
Reiter [21] Planned Parenthood 
Centers
NG vs NE unclear unclear not unclear
Rossmanith [9] Pharmaceutical company DSG vs NE unclear unclear double blind yes
Serfaty [16] Pharmaceutical company GSD vs DSG block randomisation unclear not unclear
Shoupe [15] Pharmaceutical company DSG vs NE computer generated 
random number tables
adequate double blind unclear
Singh [24] Pharmaceutical company DSG vs NE unclear unclear not yes
Weber-Diehl [25] Pharmaceutical company GSD vs NE unclear unclear not unclear
Zichella [11] Pharmaceutical company GSD vs DSG unclear unclear unclear yesReproductive Health 2004, 1 http://www.reproductive-health-journal.com/content/1/1/1
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lynestrenol, norethynodrel, cyproterone acetate and
dienogest.
Methodological quality of included studies
Methodological quality assessment was based on random
allocation technique used, blinding, post-randomization
exclusions and loss to follow-up. Each criterion was rated
as met, unmet or unclear (table 2).
Concealment of allocation
Allocation concealment was found to be adequate in one
trial [12] using sealed, opaque, sequentially numbered
envelopes.
Blinding
Four trials reported to use 'double-blinding' but there was
no mentioning of how this was achieved [9,15,17,22].
All trials randomized individuals. Two trials [16,27] rand-
omized individuals in groups of 4 and 12, respectively.
Randomization technique was clearly stated in 2 trials
[15,28]. Twelve trials used analysis by intention to treat.
Endrikat [19] reported both intention-to-treat as well as
valid case analysis. The type of analysis was unclear in two
studies [18,28]. Post randomization exclusions were not
mentioned in fifteen trials. Thirteen studies reported loss
to follow-up.
Some trials reported data on cycle control by describing
the events per cycles rather than per subjects, or the data
were given in graphical form. For the purpose of the
review we did not include these data in the review. Gener-
ally there appears to be conformity between studies in the
definitions of various cycle disturbances.
All trials except three have follow-up confined to the
course of the study with the final assessment at the end of
the concluding study cycle. Foidart [26] continued with
follow-up for three months post study, Huber [10] for six
weeks and Singh [24] for thirteen months in the des-
ogestrel/ethinylestradiol (CTR-05) arm.
Seven studies were conducted over a study duration of
twelve months, of which two [12,20] reported 18 preg-
nancies in 2438 participants. Three studies were con-
ducted over a duration of thirteen to twenty six months;
17 pregnancies were reported in 2998 subjects recruited
into the two trials reporting on it [10,26].
Comparisons and outcomes
Third- versus second-generation progestogens (see additional file 1)
Two trials were included in this comparison, comparing
monophasic gestodene (GSD) with monophasic lev-
onorgestrel (LNG) combined with 30 mcg EE [14,17]. No
pregnancies were reported in a total of 817 women fol-
lowed for six cycles. Fewer women had intermenstrual
bleeding with gestodene in the one trial reporting on it
(RR 0.71 95% CI 0.55 – 0.91) [17]. Overall, the results
between the 2 groups were similar for the following out-
comes: discontinuation (RR 0.66; 95% CI 0.41–1.05),
overall side effects (RR 1.44; 95% CI 0.68–3.04), spotting
(RR 1.11; 95% CI 0.76–1.61), breakthrough bleeding (RR
0.66; 95% CI 0.33–1.34) and absence of withdrawal
bleeding (RR 0.78; 95% CI 0.38–1.59).
Third- versus first-generation progestogens (see additional file 1)
Two trials used triphasic OCs [15,24]; and one used a
monophasic preparation [9] Overall, 976 women were
included in this comparison. Except for the two
pregnancies in women receiving norethindrone (NE) in
the Shoupe trial no other pregnancies were observed [15].
The number of women who had side effects, break-
through bleeding or discontinued was similar for the
comparison groups, for mono-and multiphasic
preparations.
Second- versus first-generation progestogens (see additional file 1)
Six trials compared levonorgestrel (LNG) or norgestrel
(NG) to norethindrone (NE) or norethisterone (NE);
three monophasic and three triphasic preparations
[8,12,20-23]. The number of women included in this
comparison is 2709 for the monophasic and 581 for the
triphasic preparations. Pregnancies occurred in one of the
2 trials reporting on it [12] with more pregnancies occur-
ring in the group receiving a first-generation progestogen
(RR 0.12, 95% CI 0.02–0.99) over a follow-up period of
one year. In the monophasic group, fewer women in the
second-generation group discontinued (RR: 0.76; 95% CI
0.67–0.86). Reported side effects and the number of
women who discontinued due to side effects were similar
in both groups for monophasic preparations; no data on
these outcomes were available for the multiphasic prepa-
rations. Cycle control appeared to be better with second
generation progestogens for both, mono-and triphasic
preparations (RR: 0.69; 95% CI 0.52–0.91) and (RR: 0.61;
95% CI 0.43–0.85), respectively.
Dunson [12] used iron tablets during the 7 days hormone
free interval in one group. The data from this trial on side
effects such as headaches, nausea/vomiting and dizziness
were therefore not included in the meta-analysis.
Comparisons of specific preparations
Gestodene versus norethindrone (triphasic)
One trial [25] with 229 women was included in this com-
parison. Fewer women had spotting in the GSD group (RR
0.59; 95% CI 0.35–0.99). Discontinuation and break-
through bleeding were similar in the 2 groups (RR 0.60;
95% CI 0.34–1.05 and RR 0.65; 95% CI 0.41–1.04). No
other data relevant for the review could be extracted.Reproductive Health 2004, 1 http://www.reproductive-health-journal.com/content/1/1/1
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Gestodene versus desogestrel (monophasic) (see additional file 1)
This comparison has the largest number of studies (seven)
and number of women (n = 5624) included
[11,13,16,19,27-29]. The two groups were similar for the
following outcomes: number of pregnancies; women who
discontinued side effects and side effects leading to dis-
continuation. More women in the GSD group discontin-
ued due to non-cycle related side effects (RR 1.81; 95% CI
1.01–3.23). Regarding cycle control, trials were further
stratified according to their estrogen dose. In one trial [13]
the estrogen dose was 15 mcg in GSD and 20 mcg in the
DSG group. The data for cycle disturbances from this trial
were therefore not included in the meta-analysis.
Gestodene versus norgestimate (monophasic) (see additional file 1)
This comparison is based on the single study by Affinito
[18], including 174 women. No pregnancies were
reported in either group at six months of OC use. Discon-
tinuation, reasons for discontinuation and overall side
effects were similar.
Desogestrel versus norethisterone (monophasic)
There is one trial included in this comparison [9]. No
pregnancies were reported in either group after 6 cycles in
a total of 118 women. Overall reported side effects were
similar in both groups.
Desogestrel versus norethindrone (triphasic)
Two trials, with a total number 858 women were included
[15,24]. No pregnancies occurred with desogestrel (0/
430) as compared to 2/428 in the group receiving nore-
thindrone. Both were described as user failures. Similar
results for side effects, discontinuation and cycle distur-
bances were reported for both groups.
Levonorgestrel versus norethindrone (monophasic)
This comparison includes 1834 women from 2 trials
[20,22]. No pregnancies occurred in either group at twelve
months of OC use. Fewer women using LNG discontin-
ued (RR 0.75; 95% CI 0.64–0.87).
Levonorgestrel versus norethindrone (triphasic)
This comparison is based on a single trial [8], including 96
women. There are no data on contraceptive effectiveness.
Fewer women had spotting (RR 0.44; 95% CI 0.20–0.97),
breakthrough bleeding (RR 0.45; 95% CI 0.24–0.85) and
intermenstrual bleeding (RR 0.53; 95% CI 0.34–0.84) in
the levonorgestrel (LNG) group.
Norgestrel versus norethindrone (monophasic)
One trial with 875 women was included in this compari-
son [12].
More pregnancies occurred with norethindrone (NE) (RR
0.12, 95% CI: 0.02–0.99) at twelve months of OC use.
Cycle disturbances as a reason for discontinuation were
less frequent in the NG group (RR 0.27, 95% CI 0.12–
0.61). Intermenstrual bleeding (RR 0.69, 95% CI 0.52–
0.91), absence of withdrawal bleeding (RR 0.29, 95% CI
0.16–0.54) and other menstrual complaints (RR 0.37,
95% CI 0.25–0.55) were less often reported in the NG
group compared to NE. Side effects were similar for both
groups.
Norgestrel versus norethindrone (triphasic)
Two trials with 485 women were included in this compar-
ison [21,23]. No data on contraceptive effectiveness were
reported. A similar number of women was satisfied with
the treatment, reported intermenstrual bleeding and
absence of withdrawal bleeding in both groups.
Drospirenone versus desogestrel (see additional file 1)
Of the 2 trials included in this comparison, one was con-
ducted over twenty six months [26] and another over thir-
teen months [10]. The total number of women
randomized was 2985. At thirteen months and at 26
months the pregnancy rate was similar in both groups. A
similar number of women in both groups reported side
effects and discontinued with the treatment.
Discussion
The aim of this systematic review was to evaluate the
acceptability of progestogens used in low-dose oral con-
traceptives. In designing the protocol for this review, we
have assumed that acceptability indices can be adequately
assessed by means of contraceptive effectiveness, cycle
control, discontinuation rates and side effects.
Effectiveness
A clinically relevant difference in effectiveness among the
different progestogens was not observed. Generally, trials
with a follow-up period of up to one year or longer
showed a failure rate ranging from 0.2 to 1.8% [12].
Continuation
The overall discontinuation rate amongst different trials
varied from 8.2% [27] to 17.9% [16] for trials using
monophasic pills and had a follow-up of 6 cycles; and
from 25.5% [12] to 28.7% [20] for trials conducted over a
follow-up period of 12 cycles. Second-generation pro-
gestogens had higher discontinuation rates compared to
third- and lower compared to first-generation prepara-
tions; which may be the reflection of a similar pattern seen
with cycle disturbances.
The association between cycle disturbances and continua-
tion has been demonstrated before. Data from longitudi-
nal studies suggest that most of the women discontinuing
OCs in the first year of use do so within the first two
months and new starters are more likely to discontinueReproductive Health 2004, 1 http://www.reproductive-health-journal.com/content/1/1/1
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than switchers. Most of the women who discontinued did
not want to fall pregnant but continued with less effective
contraceptive methods [5]. Apart from a Chlamydia tra-
chomatis infection, uterine/cervical abnormalities, smok-
ing and missing pills, low estrogenic efficacy on the
endometrium might have a causal relationship with pro-
longed spotting and breakthrough bleeding [30]. Is the
estradiol dose the sole important factor or should we con-
sider the estradiol dose in combination with the pro-
gestogen type? Each progestogen steroid differs in its
estrogenic, progestogenic and androgenic properties [31].
Spotting was reported in about 30% of women using a
combination pill with an EE content of less than 30 mcg,
as compared to about 7.5% in women using a pill with 30
mcg EE, regardless of the progestogen (GSD or DSG) con-
tent. Therefore, variation in estrogenic potential among
progestogens may explain some clinical phenomena such
as spotting and breakthrough bleeding. We were inter-
ested in the efficacy of preventing spotting and break-
through bleeding by the combination of the estrogen/
progestogen components, thus the progestogen together
with the dose of ethinylestradiol.
One trial included in this review [13] used EE 15 mcg in
one and EE 20 mcg in the other group. There was a trend
that more women in the 15 mcg group reported break-
through bleeding (RR 1.67, 95% CI 1.00–2.95), which
may be related to the lower EE dose in that group. We
were not able to lump data on spotting and breakthrough
bleeding per cycle since a woman can experience the spot-
ting during several cycles, but also several events of spot-
ting per cycle. Clustering of these data might overestimate
the outcome and distort the results.
Limitations of the review
1) There is a shortage of appropriately powered and inde-
pendently conducted randomized trials. The majority of
the trials were supported in full or partially by pharmaceu-
tical companies. The methods of allocation concealment
are unclear in most studies. 2) There is little information
in all trials on other indicators of acceptability such as
libido or sexual satisfaction scores: only one trial meas-
ured women's satisfaction with the treatment [21]. 3)
Effectiveness: Failure rate – measured as pregnancies – was
a rare outcome in all trials reporting on it. Therefore, trials
with adequate sample sizes are required to determine the
superiority of one method over the other. The included
trials in this review did not have large enough sample sizes
to detect rare outcomes. 4) Application: Assessment of
user or method failures was unlikely to be blinded and
could be biased. Most studies define user failure as two or
more missed pills in a cycle.
Also, the day of pill start, recruitment of both starters and
switchers, use of a washout period for the switchers and
the OC type received by switchers, particularly in double
blind trials, all influence cycle control data and contracep-
tive outcomes.
Unfortunately, most of these factors do not appear to have
been taken into account in these trials.
Conclusions
With 22 trials included, the total number of women
involved in most comparisons was less than 500 and the
data on the outcome variables are limited.
The third- and second-generation progestogens are pre-
ferred to first-generation progestogens in all acceptability
indices. On the basis of data from one trial, pills contain-
ing GSD may be associated with less intermenstrual
bleeding than LNG pills, but with similar patterns of spot-
ting, breakthrough bleeding and absence of withdrawal
bleeds. GSD is also comparable to DSG in contraceptive
effectiveness in the standard low dose formulation. DRSP
is comparable to DSG.
We have not come across acceptably controlled rand-
omized comparisons on other progestogens used (e.g.
cyproterone acetate). The major question as to whether
the third-generation progestogen offers an improvement
in performance over other low dose COCs, is still unan-
swered. Future research should focus on independently
conducted, well designed randomized controlled trials
with standardized inclusion criteria and outcome varia-
bles, particularly comparing the third-generation with sec-
ond-generation progestogens.
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